stockrowImmunityBio, Inc.
IBRX Healthcare Biotechnology
ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024.
- Revenue
- +93.9%
- EPS
- −120.0%
- Free cash flow
- +13.4%
- Total debt
- +57.4%
Quarter to June 2026, against a year earlier
Follow IBRX
Alert me
ImmunityBio, Inc. (IBRX) Return on equity
ImmunityBio, Inc.'s return on equity over the twelve months to 30 June 2026 was 122.9%, up 51.7 percentage points from fiscal 2025 (71.2%). Over the past ten years it has ranged from −20,269.6% (fiscal 2020) to 191.4% (fiscal 2021); the current reading is higher than 64% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 71.2% | (5.86) |
| FY2024 | 77.0% | (35.60) |
| FY2023 | 112.6% | (7.48) |
| FY2022 | 120.1% | (71.29) |
| FY2021 | 191.4% | 20,461.00 |
| FY2020 | −20,269.6% | (20,151.30) |
| FY2019 | −118.3% | (65.57) |
| FY2018 | −52.8% | (15.10) |
| FY2017 | −37.7% | (0.44) |
| FY2016 | −37.2% | 77.34 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| CYTK Cytokinetics, Incorporated compare | 184.7% |
| IBRX ImmunityBio, Inc. | 122.9% |
| TGTX TG Therapeutics, Inc. compare | 100.3% |
| KRYS Krystal Biotech, Inc. compare | 17.5% |
| PTGX Protagonist Therapeutics, Inc. compare | 11.0% |
| CAI Caris Life Sciences,�Inc. compare | 0.00% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −24.8% |
| TWST Twist Bioscience Corporation compare | −29.6% |
| SYRE Spyre Therapeutics, Inc. compare | −41.2% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on IBRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement